Abstract 337P
Background
T and NK-cell lymphoma represents approximately 10 to 15% of all non-Hodgkin’s lymphoma worldwide. However, the epidemiology of underlying subtypes varies geographically. As such, we aim to investigate disease patterns, patient demographics and survival outcomes in a multiethnic cohort from Singapore.
Methods
We performed a retrospective analysis on various histological subtypes of T and NK-cell lymphoma diagnosed from 2004 to 2022 (n=325) at the National Cancer Centre Singapore. Clinico-demographic data were collated across major ethnic groups (Chinese, Malay and Indian) and pre-defined age groups (<40, 40-65, and >65 years). Overall survival was estimated using the Kaplan-Meier method.
Results
In our study cohort, the median age was 55 years (range, 15-88), with a male predominance (61.2%). Major ethnic groups include Chinese (72.0%), followed by Malays (10.5%) and Indians (4.6%). In terms of age at diagnosis, the majority presented between ages 40 to 65 years (50.8%) in comparison to other age groups (<40 years, 24.0%) and (>65 years, 25.2%). The most common histological subtypes include angioimmunoblastic T-cell lymphoma/peripheral T-cell lymphoma T-follicular helper phenotype (AITL/PTCL-TFH) (38.8%), natural killer/T-cell lymphoma (NKTCL) (17.2%), and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) (12.6%). In analysis by age groups, AITL/PTCL-TFH was the dominant diagnosis. The next most common diagnosis was NKTCL for patients above 65 years, and was PTCL-NOS in patients under 40 years. Further analysis of ethnic distribution amongst these common subtypes revealed a similar trend, though interestingly, NKTCL was not observed amongst the Indian subgroup. In the whole cohort, the median overall survival was 21.4 years with a 5-year OS of 75.6%. 5-year OS was significantly worse for PTCL-NOS as compared to AITL/PTCL-TFH or NKTCL (62.5% vs 79.2% and 78.5%, respectively; log-rank p=0.0225). Age at diagnosis, disease stage and IPI risk groups were significantly prognostic, but not ethnic groups and sex.
Conclusions
Through this analysis we identified unique demographic and survival patterns in T and NK-cell lymphoma within our local population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Tanoto Foundation Professorship in Medical Oncology New Century Foundation Limited Ling Foundation Singapore Ministry of Health’s National Medical Research Council Research Transition Award (TA21jun-0005) and Large Collaborative Grant (OFLCG18May-0028).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study
Presenter: Tadaaki Yamada
Session: Poster Display
Resources:
Abstract
530P - MYC recruits tumor-associated macrophage to sustain metastatic malignancy of lung adenocarcinoma micropapillary subtype through epigenetic reprogramming
Presenter: Xuming Song
Session: Poster Display
Resources:
Abstract
531P - Effect of combinational targeted therapy for AXL and ATR against malignant mesothelioma cells
Presenter: Soichi Hirai
Session: Poster Display
Resources:
Abstract
532P - The changes of the serum SMRP levels is useful to predict the antitumor efficacy of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma
Presenter: Taiichiro Otsuki
Session: Poster Display
Resources:
Abstract
533P - Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs
Presenter: Teppei Yamaguchi
Session: Poster Display
Resources:
Abstract
534P - DSC2 promotes the proliferation, metastasis and drug resistance of lung cancer by activating the PI3K/AKT pathway
Presenter: Qi Li
Session: Poster Display
Resources:
Abstract
535P - Alteration in NKX2-1 CN reshapes the oncogenic, immunologic, and prognostic landscapes in NSCLC
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
536P - The evaluation and long-term outcome of pulmonary metastasectomy for osteosarcoma: A 20-year experience of Shanghai Rujin Hospital
Presenter: Zhusheng Zhang
Session: Poster Display
Resources:
Abstract
537P - The impact of treatment-free interval on patient outcome after pulmonary metastasectomy for sarcoma
Presenter: Po-Kuei Hsu
Session: Poster Display
Resources:
Abstract
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract